 BRIDGEWATER, N.J., Nov. 18, 2022 GLOBE NEWSWIRE -- VYNE Therapeutics Inc. Nasdaq: VYNE VYNE or the Company, a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that David Domzalski, President and Chief Executive Officer of VYNE, is scheduled to participate at the Piper Sandler 34th Annual Healthcare Conference on December 1, 2022, and management will host investor meetings on December 1, 2022. 